Moderna (MRNA, $73.08) gets buy rating as Jefferies analyst initiates coverage
Jefferies analyst Michael Yee initiated coverage of Moderna shares with a buy rating . Yee gave the biopharmaceutical company a share-price target of $90.
Last week, Moderna said it completed enrolling patients for a Phase II study of the vaccine candidate, mRNA-1273. Yee predicts that mRNA-1273 will have at least an emergency-use authorization by early next year.
Moderna said that it’s on track to deliver 500 million doses per year, and possibly up to 1 billion doses per year, starting 2021.
According to Tickeron, MRNA enters an Uptrend because Momentum Indicator exceeded the 0 level on July 09, 2020
This indicator signals that MRNA's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the ticker or exploring call options. In 20 of 21 cases where MRNA's Momentum Indicator exceeded 0, its price rose further within the subsequent month. The odds of a continued Uptrend are 90%.
Current price $72.74 is above $69.00 the highest resistance line found by A.I. Throughout the month of 06/09/20 - 07/10/20, the price experienced a +8% Uptrend. During the week of 07/02/20 - 07/10/20, the stock enjoyed a +7% Uptrend growth.
Technical Analysis (Indicators)
Bullish Trend Analysis
The price moved above its 50-day Moving Average, which indicates a change from a Downtrend to an Uptrend. In 9 of 9 similar backtested cases where MRNA's price crossed above its 50-day Moving Average, its price rose further within the subsequent month. The odds of a continued Uptrend are 90%.
The lower Bollinger Band was broken -- a price increase is expected as the ticker heads toward the middle band, which indicates a buy or call consideration for traders. In 7 of 8 cases where MRNA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued Uptrend are 88%.
The Aroon Indicator entered an Uptrend today. In 67 of 81 similar cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Bearish Trend Analysis
The Stochastic Indicator may be shifting from an Uptrend to a Downtrend. In 20 of 21 cases where MRNA's Stochastic indicator exited the overbought zone, the price fell further within the following month. The odds of a continued Downtrend are 90%.
The Moving Average Convergence Divergence (MACD) crossed below the signal line. In 8 of 12 cases where MRNA's MACD histogram became negative, the price fell further within the following month. The odds of a continued Downtrend are 67%.
Fundamental Analysis (Ratings)
Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 79%. During the last month, the daily ratio of advancing to declining volumes was 1.43 to 1.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.12) is normal, around the industry mean (53.25). P/E Ratio (0.00) is within average values for comparable stocks, (64.53). Projected Growth (PEG Ratio) (0.00) is also within normal values, averaging (4.87). Dividend Yield (0.00) settles around the average of (0.08) among similar stocks. P/S Ratio (201.16) is also within normal values, averaging (1247.73).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MRNA's RSI Oscillator recovers from overbought zone
The 10-day RSI Oscillator for MRNA moved out of overbought territory on January 08, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 instances where the indicator moved out of the overbought zone. In of the 36 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where MRNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
MRNA moved below its 50-day moving average on January 08, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRNA broke above its upper Bollinger Band on January 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on January 02, 2025. You may want to consider a long position or call options on MRNA as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.099) is normal, around the industry mean (14.785). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.844). MRNA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (2.579) is also within normal values, averaging (264.102).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MRNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of transformative medicines for patients
Industry Biotechnology